Popular Filters
Trials for Metastatic Patients
Molecular Profiling
Molecular Profiling for Brain Tumor
Recruiting1 award9 criteria
San Diego, California
This trial will test a new treatment approach for children with High-grade gliomas HGG that is based on each patient's tumor gene expression, whole-exome sequencing (WES), targeted panel profile (UCSF 500 gene panel), and RNA-Seq.
Behavioral Intervention
Telehealth Consultations for Brain Cancer
Recruiting1 award2 criteria
Rochester, New York
This trial will create an Early START visit for patients with high grade gliomas to discuss end of life wishes soon after their initial oncology visit. A checklist and pre-visit guide will be used to help guide the visit for both the provider and patient.
Chemotherapy
PF-07799933 for Advanced Cancers
Recruiting1 awardPhase 1
Fayetteville, Arkansas
This trial tests a new medicine, PF-07799933, for people with advanced solid tumors that have a specific gene issue and haven't responded to other treatments. Participants will take PF-07799933 as a tablet regularly, and some may also take binimetinib or receive cetuximab shots. The goal is to see if these medicines are safe and effective.
Trials for BRAF Positive Patients
Chemotherapy
PF-07799933 for Advanced Cancers
Recruiting1 awardPhase 1
Fayetteville, Arkansas
This trial tests a new medicine, PF-07799933, for people with advanced solid tumors that have a specific gene issue and haven't responded to other treatments. Participants will take PF-07799933 as a tablet regularly, and some may also take binimetinib or receive cetuximab shots. The goal is to see if these medicines are safe and effective.
Chemotherapy
PF-07799544 for Cancer
Recruiting1 awardPhase 1
Fayetteville, Arkansas
This trial tests a new cancer medicine, PF-07799544, taken regularly as a tablet. It is for people with advanced solid tumors who haven't responded to other treatments. The medicine may be used alone or with other drugs to improve its effectiveness.
Kinase Inhibitor
Vemurafenib for Pediatric Brain Cancer
Recruiting1 awardPhase < 1
Los Angeles, California
This trial is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of vemurafenib in children with recurrent or refractory gliomas containing the BRAFV600E or BRAF Ins T mutation.
Kinase Inhibitor
Selumetinib for Pediatric Brain Cancer
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing a new drug to treat young patients with brain cancer that has come back or does not respond to treatment. The drug may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Vinca alkaloids
Vinblastine + Bevacizumab for Brain Tumor
Recruiting3 awardsPhase 2
Los Angeles, California
This trial is testing if adding Bevacizumab to Vinblastine helps children with worsening brain tumors more than using Vinblastine alone. Vinblastine is given regularly, and Bevacizumab is added periodically for several months. Bevacizumab is an anti-VEGF antibody approved for treating various cancers and has been studied for use in children with brain tumors.
Radiation
Dabrafenib + Trametinib After Radiation for Brain Cancer
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial studies how well dabrafenib and trametinib work after radiation therapy in children and young adults with a specific type of brain tumor. These drugs help stop tumor growth by blocking signals that tell the cells to multiply. Dabrafenib has been developed and tested extensively for a specific type of skin cancer, showing effectiveness both alone and when used with trametinib.
Phase 3 Trials
Alkylating agents
Carboplatin Regimens for Brain Tumors
Recruiting4 awardsPhase 3
Phoenix, Arizona
This trial is investigating whether the chemotherapy drug carboplatin is as effective as the current standard treatment for Low Grade Glioma (LGG) in children and young adults. Previous studies suggest that carb
MEK Inhibitor
Selumetinib vs. Chemotherapy for Brain Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.